The blood-clotting protein prothrombin can be converted to thrombin in free solution by the proteolytic enzyme, activated factor X. When prothrombin is bound to the surface of phospholipid vesicles, the rate of thrombin generation is increased more than 30-fold over the rate of unbound prothrombin. If the prothrombin activation process is terminated after a time interval in which less than 10% of the expected thrombin has been produced, two major products are found in the activation mixture. These products have been termed intermediate 1, a precursor of thrombin, and fragment 1. The conversion of prothrombin to thrombin in the blood coagulation process is markedly accelerated in the presence of phospholipid vesicles (1-3). Both prothrombin (3, 4) and activated factor X (the enzyme catalyzing the proteolyses involved in thrombin formation) (5) bind to phospholipid particles. This binding requires divalent cations and is reversible by removal of the divalent cations. In contrast to prothrombin, the final active product of the activation process, thrombin, does not bind to phospholipid surfaces (3,4).
The conversion of prothrombin to thrombin in the blood coagulation process is markedly accelerated in the presence of phospholipid vesicles (1) (2) (3) . Both prothrombin (3, 4) and activated factor X (the enzyme catalyzing the proteolyses involved in thrombin formation) (5) bind to phospholipid particles. This binding requires divalent cations and is reversible by removal of the divalent cations. In contrast to prothrombin, the final active product of the activation process, thrombin, does not bind to phospholipid surfaces (3, 4) .
Investigations into the prothrombin activation mechanism have demonstrated the existence of at least two intermediates between prothrombin and thrombin and two activation fragments (6) (7) (8) (9) (10) . As the relationship of some of the products described in earlier investigations to those seen by sodium dodecyl sulfate-acrylamide gel electrophoresis (8) (9) (10) is not clearly established, no simple or universally accepted way of describing the activation intermediates and fragments exists. Intermediates are defined here as partial activation products that can be further activated to yield thrombin. These intermediates, which have been defined principally on the basis of the order of their appearance during prothrombin activation by use of Na dodecyl sulfate-acrylamide gel electrophoresis (7) (8) (9) (10) , are phenomenological intermediates and not necessarily kinetic intermediates in the activation process under all conditions. Activation fragments are, in contrast, those products that are not precursors of thrombin.
The phenomenological scheme (Owen, W. G., Esmon, C. T. & Jackson, C. M., manuscript in preparation) t is summarized as follows:
Prothrombin Intermediate 1 and fragment 1 can be formed by the action of thrombin on prothrombin in both the presence and absence of factor Xa; however, factor Xa is required to form thrombin from prothrombin or either of the intermediates. Interaction between phospholipid vesicles and the activation products from partial activation of prothrombin with factor Xa were investigated in this study.
MATERIALS AND METHODS
Oleic acid (>99% purity), phospholipase D, bovine-serum albumin, Russell's viper (Vipera russellii) venom, and Tris * HCl were obtained from Sigma Chemical Co. DEAESephadex was a product of Pharmacia, and Bio-Gel A 0.5 m was obtained from Bio Rad Laboratories. Dialysis tubing was a product of Union Carbide Corp., and silica gel GF-254 was a product of E. Merck Darmstadt. Preparative thin-layer chromatography (TLC) plates were obtained from Analtech Inc. All common laboratory chemicals were of analytical reagent grade and were obtained from major domestic supply houses. Bovine brain "cephalin" was prepared by the procedure of Folch (11) .
Bovine factor X was purified (12) and activated with the factor X coagulant protein from Russell's viper venom (13) .
Factor Xa was separated from the venom enzyme by chromatography on DEAE-Sephadex A50 (14) . Prothrombin was isolated from bovine plasma by a modification of the procedure of Cox and Hanahan (15 (17) , and in Na dodecyl sulfate-acrylamide gel electrophoresis, with the system described by Laemmli (18) . Dioleoyl lecithin was synthesized from oleic anhydride (19) and glycerophosphorylcholine (20) by the method of Cubero Robles and Van Den Berg (21) . The lecithin was purified by chromatography on silicic acid (22) and A1203 (23) . The product was homogeneous by TLC on silica gel G with CHC13-MeOH-H20 6.5:2.5:0.4 (v/v/v) solvent (24) .
Dioleoylphosphatidylglycerol was synthesized from dioleoyl lecithin with phospholipase D (25) (26) . The ratio of glycerol (27) to phosphate (28) -in the synthetic dioleoylphosphatidylglycerol was 1.9:1 (theoretical 2: 1).
Dioleoylphosphatidylethanolamine was also synthesized from dioleoyl lecithin with phospholipase D (25) . This compound was isolated by preparative TLC with the solvent systems described above for phosphatidylglycerol. The final product was homogeneous by TLC.
Phospholipid concentrations were obtained from total phosphate determinations (28) .
Protein concentrations were determined by the procedure of Lowry et al. (29) , by absorbance at 280 nm, and by ninhydrin assay after alkaline hydrolysis (30, 31) . Prothrombin and activation intermediates were assayed after conversion to thrombin, with Taipan snake venom and phospholipid (32) . The thrombin was assayed by its ability to clot bovine fibrinogen prepared by the procedure of Straughn and Wagner (33) . Fibrinogen was used as a 2 mg/ml solution in 10 mM Tris HCl (pH 7.5). Thrombin activity was quantitatively defined from a calibration curve constructed with NIH standard thrombin, lot 3B.
Preparation of Phospholipid Dispersions. Dioleoylphosphatidylcholine and dioleoylphosphatidylglycerol were dissolved in CHC13. The solutions were mixed such that the mole ratio of the phosphatidylglycerol to the phosphatidylcholine was 1:1. Phospholipid dispersions were prepared by addition of 1 ml of the appropriate buffer for the binding experiment to an ampoule containing 4 Under these conditions no degradation of the phospholipids could be detected by TLC with the previously described solvents.
Lipid-Protein Binding Technique. Protein binding was determined by published methods (4, 5) . In this investigation all studies were performed with a 0.9 X 30-cm column of Biogel Agarose A 0.5 m equilibrated with Tris * HCl buffer ( . Effect of phospholipid on the rate of thrombin generation from prothrombin. Prothrombin (0.3 mg/ml) was incubated with factor Xa (40 ,ug/ml) and phospholipid (as specified in the figure). Phospholipid was an equimolar mixture of phosphatidylcholine and phosphatidylglycerol. The reactions were performed at 280 in a buffer containing 20 mM Tris-HCl (pH 7.5)-100 mM NaCl-10 mM CaCl2. Thrombin activity, e *. (3, 4) , no binding could be demonstrated (Fig. 4B ).
FIG. 2 (right
It appears from these data that the absence of an effect of phospholipid on the rate of conversion of intermediate 1 to thrombin is related to the conversion of prothrombin from a protein capable of binding phospholipid to a species that has lost this capacity.
On the basis of the phenomenological mechanism described earlier, the above observations suggest that-the fragment produced from prothrombin concomitant with intermediate 1 might be responsible for the binding of prothrombin to the lipid surface. The results of the fragment 1-phospholipid binding experiments are shown in Fig. 5A . The appropriate control for a Ca2+-free buffer is shown in Fig. 5B , and the demonstration that cochromatography of fragment 1 and phospholipid is not due to aggregation of fragment 1 in the presence of Ca2+ is shown in Fig. 5C . Fragment 2, the other activation fragment, does not bind to phospholipid vesicles (data not shown).
Two additional considerations are required to establish the general significance of these results. First, binding of prothrombin and fragment 1 to phospholipid should occur not only at the optimum Ca2+ concentration for the activation process, i.e., 10 mM (10), but should be demonstrable at concentrations comparable to those of plasma, i.e., 2 mM (38) . Table 1 and phosphatidylcholine/phosphatidylglycerol (4 mg/ml) were mixed and allowed to equilibrate for 30 min. 0.25 ml was applied to the Biogel column. The sample and column were equilibrated in 40 mM Tris HCl (pH 7.2)-70 mM NaCi-10 mM CaCl2-0.02% NaN3; 0.5-ml fractions were collected. Thrombin activity, * *; phospholipid, *-.*. (B) Equal volumes of thrombin (0.4 mg/ml) and phosphatidylcholine/phosphatidylglycerol (4 mg/ml) were mixed, and 0.25 ml was applied to the column. All other conditions were the same as in (A). Thrombin activity, *--*; phospholipid, *...*. that binding occurs with vesicles prepared from other types of phospholipids. Table 1 contains the data obtained from experiments on the binding of prothrombin and fragment 1 to mixtures of synthetic phosphatidylethanolamine and phosphatidylglycerol and to a preparation of crude bovine brain "cephalin."
DISCUSSION
The ability of phospholipid to increase the rate of thrombin formation from prothrombin appears to arise as a direct consequence of the binding of prothrombin to phospholipid particles. Two primary types of evidence for this conclusion have been presented: (i) the loss of the accelerating effect of phospholipid on the conversion of intermediate 1 to thrombin concomitant with the loss in ability of intermediate 1 to bind to phospholipid, and (ii) the direct demonstration that fragment 1, a nonthrombin-forming activation product, binds to phospholipid under the same conditions as prothrombin. On the basis of these observations, we suggest that binding of prothrombin to phospholipid occurs as a con- (PS/PE) Thrombin PG/PC 10 0 * All binding experiments were performed at 23-25°. Equal volumes of protein and phospholipid (4 mg/ml) were mixed and permitted to equilibrate for 30 min. A sample of the particular mixture (0.25 ml) was then applied to the Biogel A 0.5 m column (0.9 X 30 cm), and 0.5-ml fractions were collected. The phospholipid type and CaCl2 concentration is given in the table; zero CaCl2 is 1.5 mM EDTA. Prothrombin was used at a concentration of 1.2 mg/ml, intermediate 1 at 1.5 mg/ml, and thrombin at 0.4 mg/ml.
The Biogel columns were equilibrated with 40 mM Tris* HCl (pH 7.2)-70 mM NaCl-0.02% NaNa. Fragment 1 was used at a concentration of 1.5 mg/ml, and the Biogel and protein were equilibrated with 4 mM Tris-HCl (pH 7.2)-106 mM NaCl-0.02% NaNs. to lipid surface. If this is so, the kinetic mechanism will differ from the phenomenological mechanism, which is based primarily on mass balance. Another possibility is that local concentration and orientation effects may be responsible for the increased rate when the proteins are adsorbed to the phospholipid surface. Unfortunately, this last possibility may be very hard to test in view of the limited techniques now known for following the prothrombin activation process. Bovine factor X, the zymogen of the protease responsible for prothrombin activation, is made up of two disulfidelinked polypeptide chains (42) . The heavy chain of factor X, which is the chain containing the active site in factor Xa (43) , possesses an aminoacid composition strikingly similar to that of thrombin (42) . The light chain of factor X has an aminoacid composition similar to that of fragment 1 (Jackson, unpublished observations). Since factor Xa binds to phospholipid (5), it is possible that the light chain of factor X may be involved in lipid binding.
Prothrombin isolated from cows fed the vitamin K antagonist, dicoumarol, is activated extremely slowly in comparison to prothrombin from normal animals (44, 45) . However, with nonphysiological activators, the thrombin formed from this "abnormal prothrombin" is indistinguishable in its catalytic activity from the "normal" thrombin (45) . A recent report by Nelsestuen and Suttie (46) has demonstrated a striking difference in Ca2+ binding between the two prothrombins, whereas no other chemical differences could be found (47) . In view of the Ca2+ requirement for binding of prothrombin and fragment 1 to lipid and the lipid effect on prothrombin activation rate described here, it becomes interesting to ask if vitamin K action, prothrombin activation rate, calcium binding to prothrombin, and lipid acceleration of prothrombin activation are related phenomena. If this is found to be so, the chemical function of vitamin K may be more readily determinable.
